Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00091546 · ClinicalTrials.gov registry record

Genetic and Environmental Characteristics of Primary Pulmonary Hypertension

A clinical trial, sponsored by Vanderbilt University.

Completed
Registry status
3,000
Enrollment target

NCT00091546 is a clinical trial that has completed, run by Vanderbilt University. The registered enrollment target is 3,000 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00091546 has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
3,000 participants
Enrollment target

Study Summary

The goal of this study is to identify the modifying genes and environmental features that regulate the clinical expression of mutations in bone morphogenetic protein receptor 2 (BMPR2); to develop the understanding of how BMPR2 mutations result in disease; and to identify the undiscovered genetic mutations that cause primary pulmonary hypertension (PPH).

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2003-08
Est. Completion 2009-07

Sponsor

Vanderbilt University

430 total trials

What the Registry Record Tells You About NCT00091546

The ClinicalTrials.gov registry entry for NCT00091546 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00091546 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00091546 about?

NCT00091546 is a clinical study titled "Genetic and Environmental Characteristics of Primary Pulmonary Hypertension". The goal of this study is to identify the modifying genes and environmental features that regulate the clinical expression of mutations in bone morphogenetic protein receptor 2 (BMPR2); to develop the understanding of how BMPR2 mutations result in disease; and to identify the undiscovered genetic mu...

What is the current status of trial NCT00091546?

This trial is currently completed. The enrollment target is 3,000 participants. The study started on 2003-08. Estimated completion is 2009-07.

Who is sponsoring clinical trial NCT00091546?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.